Xiaolong Q. Yan
1 Xinsi Road
Xi'an, 710038, China
Xi'an, 710038, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Correction: Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.
Journal: BMC cancer
Published: August 01, 2026
Machine learning-driven development of a novel unfolded protein response-related gene signature for predicting lung adenocarcinoma patient prognosis.
Journal: BMC cancer
Published: March 16, 2026
Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF-1α-glycolysis axis to mediate anti-PD-1 resistance in non-small cell lung cancer.
Journal: Clinical and translational medicine
Published: October 16, 2025
Lobectomy-first versus lymphadenectomy-first on long-term survival for operable non-small cell lung cancer: protocol of LOFTY trial.
Journal: Trials
Published: July 24, 2025
Circ_0074158 and QKI6: A regulatory axis for PD-L1 ubiquitination and immune evasion in NSCLC.
Journal: Cancer immunology, immunotherapy : CII
Published: July 08, 2025
The tryptophan metabolite indole 3-propionic acid alleviates lung ischemia-reperfusion injury via prostaglandin reductase 2 in male mice.
Journal: Biochemical pharmacology
Published: June 30, 2025
A single-cell atlas reveals the tumorigenesis and microenvironment status of primary tracheobronchial tumors.
Journal: NPJ precision oncology
Published: June 11, 2025
Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.
Journal: BMC cancer
Published: May 18, 2025
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting.
Journal: Experimental hematology & oncology
Published: April 05, 2025
Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer.
Journal: Clinical lung cancer
Published: March 07, 2025
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial).
Journal: Signal transduction and targeted therapy
Published: March 06, 2024
Postoperative complications and mortality after thoracic surgery of COVID-19 omicron hospital infections: A retrospective multicenter study.
Journal: Current problems in surgery
Published: February 07, 2024
Last Updated: 09/26/2026